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Background: The purpose of this study was to evaluate the efficacy and duration of action of 
once-daily dosing with alcaftadine 0.25% ophthalmic solution and olopatadine 0.2% ophthalmic 
solution as compared with placebo in the prevention of ocular itching, and to directly compare 
the efficacy of alcaftadine 0.25% with olopatadine 0.2% in the prevention of ocular itching 
associated with allergic conjunctivitis using the conjunctival allergen challenge model.
Methods: Subjects with allergic conjunctivitis (n = 127) were enrolled in a multicenter, 
double-masked, randomized, active-controlled and placebo-controlled clinical trial. Using the 
conjunctival allergen challenge model, this study was conducted over the course of approxi-
mately 5 weeks. Subjects were randomized into one of three treatment arms: alcaftadine 0.25% 
ophthalmic solution, olopatadine 0.2% ophthalmic solution, or placebo. Study medications 
were administered twice over the course of the trial. The primary efficacy measure for the study 
was ocular itching evaluated by the subject at 3, 5, and 7 minutes post challenge. Secondary 
endpoints, measured at 7, 15, and 20 minutes post challenge, included conjunctival, ciliary, and 
episcleral redness, lid swelling, chemosis, and tearing. Duration of action was measured at 16 
and 24 hours post-instillation of the study medication at visits 3 and 4, respectively.
Results: For the primary measure of ocular itching, both actives, alcaftadine 0.25% and olopa-
tadine 0.2%, were statistically superior to placebo at all three measured time points for both the 
16-hour and 24-hour measures (P , 0.0001). Eyes treated with alcaftadine 0.25% had numerically 
lower mean ocular itching scores than eyes treated with olopatadine 0.2% at every time point, and 
this difference was statistically significant at the 3-minute time point 16 hours post instillation 
(P = 0.026). Eyes treated with alcaftadine 0.25% and with olopatadine 0.2% displayed significantly 
less lid swelling relative to placebo at every time point for the 16-hour and 24-hour post-instillation 
visits (P , 0.005). Alcaftadine 0.25% was the only active treatment that provided statistically 
significant relief of chemosis at every time point of the 24-hour post-instillation visit.
Conclusion: Both the alcaftadine 0.25% and olopatadine 0.2% ophthalmic solutions provided 
highly effective relief of ocular itching at both 16 and 24 hours post-instillation. Treatment 
differences between the actives were most pronounced at the earliest time point (3 minutes 
post-challenge) following conjunctival allergen challenge (16 hours), when alcaftadine 0.25% 
ophthalmic solution was statistically superior to olopatadine 0.2% ophthalmic solution. Alcaftadine 
0.25% was the only treatment to provide significant relief from chemosis at both 16 and 24 hours 
post-instillation. Both active treatments and placebo were generally safe and well tolerated.
Keywords: alcaftadine 0.25%, olopatadine 0.2%, conjunctival allergen challenge model
Introduction
Allergic conjunctivitis is the most common allergic disorder of the eye, with an 
estimated 60 million affected individuals in the US.1 The hallmark symptom of the 
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disease is ocular itching, but patients typically experience 
a combination of conditions including conjunctival hyper-
emia, lid swelling, excessive tearing, chemosis, rhinorrhea, 
and nasal congestion.2 Affected individuals are those with 
either seasonal or perennial allergies. Exposure to allergens, 
such as pollens, dust mites, or animal dander elicits an IgE-
based hypersensitivity response. This triggers the release 
of histamine and other pro-allergic and pro-inflammatory 
mediators.2
Mast cells of the immune system are found throughout 
the body, including the substantia propria of the conjunctiva.3 
Allergen binding to specific IgE molecules triggers mast 
cell degranulation and the subsequent increase in histamine 
leads to activation of both H
1
-type and H
2
-type histamine 
receptors.2–4 These stimulate itching and vasodilation, respec-
tively, thereby initiating a response that may last minutes or 
hours. With prolonged or repeated allergen exposure, the 
conjunctiva may become infiltrated by inflammatory cells 
that promote continued symptoms and eventual disruption 
of epithelial integrity.5
Antihistamines remain at the forefront of the therapeutic 
options for treating allergic conjunctivitis because of the 
central role of histamine in the pathogenesis of both itching 
and vasodilation. Currently available antagonists of hista-
mine receptor activation have significant benefit in relieving 
the signs and symptoms of allergic conjunctivitis, and are 
particularly effective in relieving ocular itching.4 Another 
advantage of these compounds is that many can be formulated 
for topical delivery, reducing the adverse effects associated 
with systemic formulations.6,7 Two topical antihistamines 
currently approved for once-daily use in the US, olopatadine 
hydrochloride 0.2% and alcaftadine 0.25%, are the focus of 
the study reported herein.
Both olopatadine 0.2% and alcaftadine 0.25% are clas-
sified as dual-action antiallergic medications, meaning they 
act both directly to inhibit histamine receptor activation 
and indirectly to reduce allergic responses by attenuating 
mast cell degranulation.4,7 Olopatadine was first used in 
a formulation strength of 0.1% and indicated for twice-
daily use. A more concentrated formulation of 0.2% was 
later approved for once-daily treatment of ocular itching 
associated with allergic conjunctivitis.8 Alcaftadine 0.25% 
ophthalmic solution was approved by the FDA in 2011 as 
a once-daily therapeutic treatment for the prevention of 
itching associated with allergic conjunctivitis.9 These are 
the only topical antihistamines with this long duration of 
action currently available.
Olopatadine 0.2% and alcaftadine 0.25% approvals for 
once-daily use in the US were based upon clinical trials in 
which efficacy was demonstrated 16 hours post-instillation 
utilizing the conjunctival allergen challenge (CAC) model 
of allergic conjunctivitis.10,11 The CAC model provides a 
controlled alternative to environmental allergy trials that 
depend on variable allergen exposures and subjective 
patient-reported efficacy measures. It has been utilized 
in over 100 clinical trials, and has become a standard 
for the US Food and Drug Administration approval of 
ophthalmic antiallergics.12 The goal of this study was to 
evaluate the efficacy of once-daily antihistamines beyond 
the established 16-hour post-instillation time point. This 
study was designed to evaluate the efficacy and duration 
of action of alcaftadine 0.25% ophthalmic solution and 
olopatadine 0.2% ophthalmic solution as compared with 
placebo in the prevention of ocular itching at both 16 and 
24 hours post instillation, and to directly compare the 
efficacy of alcaftadine 0.25% with olopatadine 0.2% in 
the prevention of ocular itching associated with allergic 
conjunctivitis using CAC.
Materials and methods
Study design
This study (ClinicalTrials.gov identifier NCT01470118) 
protocol employed a multicenter, double-masked, 
randomized, active-controlled and placebo-controlled 
design. Key features of the protocol design are similar to 
those in previous studies of alcaftadine,11 with key differ-
ences based on the timing of allergen challenge relative to 
instillation of study medication; allergen challenges were 
conducted 16 and 24 hours after treatment instillation to 
assess treatment efficacy.
Three treatments were used in this comparative study. 
The two actives were alcaftadine 0.25% ophthalmic solution 
(Lastacaft®, Allergan Inc, Irvine, CA, USA) and olopatadine 
0.2% ophthalmic solution (Pataday™, Alcon Laboratories 
Inc, Fort Worth, TX, USA), and the placebo was 0.3% 
hydroxypropyl methylcellulose (Tears Naturale® II, Alcon 
Laboratories Inc). The protocols and informed consent were 
both investigational review board-approved (Alpha IRB, San 
Clemente, CA, USA). Three sites were used for the trials and 
they were conducted in accordance with International Confer-
ence on Harmonisation, Good Clinical Practice guidelines 
and the Declaration of Helsinki. All subjects had to be at 
least 10 years of age, and had to provide written, informed 
consent (and assent if applicable).
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Eligibility criteria
Key subject inclusion was based upon entry criteria outlined 
as follows: subjects were required to have a history of ocular 
allergies and at least one positive skin test to at least one of 
the allergens which included cat hair, cat dander, grasses, 
ragweed, dog dander, cockroach, dust mites, and trees within 
24 months of the trial start date. All subjects were also 
required to have best-corrected visual acuity $ 0.6 on the 
logMAR (Early Treatment Diabetic Retinopathy Study chart, 
ETDRS) scale, and all agreed to avoid disallowed medication 
and contact lens wear for the designated period. Subjects 
underwent two allergen challenge visits during screening. 
In order to be included in the trial, subjects were required to 
exhibit a positive, bilateral reaction (itching and conjunctival 
redness scores $ 2, see below) to the CAC within 10 minutes 
of allergen instillation at both visit 1 and visit 2.
Key exclusion criteria included any baseline itching or 
redness . 1 in any vessel at each visit, any known allergy, 
contraindications or sensitivity to any of the study medica-
tions, or any systemic or ocular condition in the opinion 
of the investigator that could have affected safety or trial 
parameters. Exclusion criteria also included ocular surgery 
within 3 months or refractive surgery within 6 months, or 
if subjects exhibited any signs of active allergic conjuncti-
vitis at the start of any visit, had an active ocular infection 
 (bacterial or viral), or history of herpetic ocular disease. 
The use of any prohibited topical or systemic medications 
during the designated period or concurrent enrollment in 
any other clinical trial excluded the subject from the study. 
Due to the potential for randomization into a treatment arm 
with a pregnancy category C therapeutic,8 women who were 
pregnant, planning a pregnancy, lactating, or not using a 
medically acceptable form of birth control for the entire 
period of the trial were excluded from the study. Subjects 
planning surgical procedures during the trial period or 
with a history of retinal detachment, diabetic retinopathy, 
or progressive retinal disease were also ineligible. Based 
upon these inclusion and exclusion criteria, three study sites 
screened a total of 245 subjects. A total of 127 subjects were 
eligible for randomization in a 1:1:1 ratio corresponding to 
the three treatments.
Allergen challenge and assessment  
of treatment efficacy
Allergen challenge employed a five-point scale for severity 
of ocular itch, where 0 indicated no itch and 4 indicated an 
incapacitating itch with an insatiable desire to rub. This scale, 
which allows for half-unit measures, has been used in CAC 
studies previously.10–18 Ocular redness was scored by an inves-
tigator using a five-point ocular redness scale (0–4) where 
0 = none and 4 = extremely severe with large, numerous, 
dilated blood vessels characterized by an unusually severe 
deep red color. This scale has been used to grade ocular 
redness in previous studies.10–18
For the first study visit (visit 1), subjects received bilateral 
ocular instillation of antigen, followed by subject-reported 
assessment of itching 10 minutes after instillation. Subjects 
were titrated with increasing allergen concentrations until 
the scores for both itching and redness reached $ 2.0. The 
maximal allergen concentration used in the visit 1 titration 
was used for all subsequent visits. All study visits included 
medical history updates and ocular health assessment (visual 
acuity measurement and slit-lamp examination).
At visit 2, a second allergen challenge provided base-
line data for those subjects who continued to satisfy eli-
gibility criteria. Following the challenge, subjects graded 
their ocular itching at 3, 5, and 7 minutes after allergen 
instillation, while the secondary endpoint measures of 
investigator-assessed conjunctival redness and chemosis 
and subject-assessed lid swelling and tearing were at 7, 
15, and 20 minutes. Subjects who met the screening crite-
ria (scores $ 2 for both itching and conjunctival redness 
within 10 minutes of CAC) at visit 2 continued to visit 3A, 
approximately 2 weeks after visit 2.
At visit 3A, subjects who qualified were randomized and 
received one drop of masked treatment (either alcaftadine 
0.25%, olopatadine 0.2%, or placebo) in each eye. Subjects 
returned approximately 15.5 hours after treatment instilla-
tion for the visit 3B CAC. Sixteen hours after instillation of 
treatment, subjects’ eyes were challenged by instilling one 
drop of the allergen solution bilaterally. Ocular itching was 
graded by subjects at 3, 5, and 7 minutes after instillation. 
Secondary efficacy variables, ie, redness, chemosis, tearing, 
and lid swelling, were evaluated at 7, 15, and 20 minutes. 
Conjunctival, ciliary, and episcleral redness as well as 
chemosis were graded by the investigator, and lid swelling 
and tearing were graded by the subject.
Fourteen days later (± 3 days), subjects returned for visit 
4A. Following ocular health assessments, study staff instilled 
one drop of masked treatment into each eye and the subjects 
returned in 23.5 hours for visit 4B. Twenty-four hours after 
treatment instillation, subjects were again  challenged with 
one drop of allergen solution bilaterally and then assessed 
for primary and secondary variables as in previous visits.
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Efficacy and safety measures
The primary efficacy variable was ocular itching, which 
was quantified by the subjects using a 5-unit (0–4 units) 
standardized scale, with half-unit increments allowed. 
Secondary endpoints of conjunctival redness, ciliary red-
ness, episcleral redness, and chemosis, were graded by the 
investigator using a 0–4 scale in which half unit values were 
allowed. Lid swelling employed a 0–3 scale without half-unit 
increments, and ocular tearing was scored using a 0–4 scale 
without half-unit increments. Safety assessments included the 
visual acuity measure using an ETDRS chart, slit-lamp bio-
microscopy examination, and adverse event assessments.
Data analysis and statistical methods
Study population information and medical histories included 
both quantitative data such as age and qualitative demographics. 
Quantitative data were analyzed using a two-sided t-test, while 
qualitative demographic variables were analyzed using Fisher’s 
Exact test or Chi-squared test. The intent-to-treat population 
(Table 1) was defined as those who were randomized at the 
beginning of visit 3. Per protocol subjects were those who 
completed the study with no major protocol violations.
The primary efficacy measure was ocular itching and the 
primary endpoint was mean ocular itching at 16 and 24 hours 
post instillation of the study medication, and 3, 5, and 7 min-
utes post CAC. Data collected at visit 3B and visit 4B were 
used for analysis of the primary endpoint. Predefined analysis 
of the primary efficacy data included comparison of the number 
of subjects in each treatment group with minimal itch, defined 
as those with itch scores , 1, and the number of subjects with 
zero itch, defined as scores = 0. These analyses used Fisher’s 
Exact test for each pairwise treatment comparison (alcaftadine 
0.25% versus placebo, olopatadine 0.2% versus placebo, and 
alcaftadine 0.25% versus olopatadine 0.2%). Descriptive 
statistics (number of observations, mean, standard deviation, 
median, minimum, and maximum values) for the primary 
efficacy variable were summarized by visit, time point, and 
treatment group. Secondary endpoints were summarized using 
descriptive statistics and analyzed using the same statistical 
methods as those used for the primary endpoints.
A sample size of 40 subjects in each treatment group was 
determined to provide approximately 99% power to detect a dif-
ference in means of 1.00 unit (the difference between placebo 
and alcaftadine 0.25%, and the difference between placebo 
and olopatadine 0.2%) assuming that the common standard 
deviation is 1.00 unit using a two-sample t-test with a 0.05 
two-sided significance level. A sample size of 40 subjects in 
each treatment group was determined to provide approximately 
87% power to detect a difference in means of 0.70 unit between 
alcaftadine 0.25% and olopatadine 0.2%.
Results
A total of 127 subjects were enrolled in the study following 
screening visits 1 and 2, and 115 completed the study. Both 
Table 1 Demographics (intent-to-treat population)
Characteristic Alcaftadine 0.25% 
n = 43
Olopatadine 0.2% 
n = 43
Placebo 
n = 41
All subjects 
n = 127
P value
Age 0.634
 Mean ± SD 39.3 ± 12.4 37.0 ± 14.8 39.3 ± 12.3 38.5 ± 13.2
 Min–max 15–64 12–74 14–61 12–74
Gender, n (%) 0.726
 Male 12 (28) 10 (23) 13 (32) 35 (28)
 Female 31 (72) 33 (77) 28 (68) 92 (72)
Ethnicity, n (%) 0.496
 Hispanic or Latino 5 (11.6) 9 (20.9) 5 (12.2) 19 (15)
 not Hispanic or Latino 38 (88.4) 34 (79.1) 36 (87.8) 108 (85)
Race, n 0.316
 African American 5 2 6 13
 Caucasian 34 34 33 101
 Other 4 7 2 13
Iris color, n 0.062
 Blue 20 24 16 60
 Brown 50 46 46 142
 Hazel 4 12 6 22
 Green 12 4 12 28
 Gray 0 0 2 2
Abbreviations: min, minimum; max, maximum; P, probability level; SD, standard deviation.
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Figure 1 Comparison of ocular itching scores at 16 hours (A) and at 24 hours 
(B) after instillation of treatment. Mean itching for placebo, alcaftadine 0.25%, and 
olopatadine 0.2% at 3, 5, and 7 minutes after allergen challenge.
active treatment arms had 38 (88%) subjects complete the 
study, and 39 (95%) completed in the placebo group. Of 
the 127 subjects enrolled in the intent-to-treat population, 
12 subjects did not complete the study; of these, three were 
because of non-treatment-related adverse events, eight 
because of administrative issues, and two because of other 
non-study-related issues. The demographic characteristics 
of the groups revealed no significant differences between 
treatment groups with respect to age, gender, race, or iris 
color (Table 1).
The primary endpoint for this study was mean ocu-
lar itching at 3, 5, and 7 minutes post CAC at 16 and 
24 hours post instillation of treatment (Figure 1; Table 2). 
Sixteen hours after treatment instillation, both actives 
were statistically superior to placebo (P , 0.0001). The 
same statistical superiority compared with placebo was 
observed for active treatments 24 hours after instillation 
(P , 0.0001).  Comparison of the two actives demon-
strated that alcaftadine 0.25% achieved numerically 
lower mean itch scores than  olopatadine 0.2% at all 
Table 2 Summary of ocular itching results (intent-to-treat population): differences versus placebo in mean ocular itching scores 
following CAC for alcaftadine 0.25% and olopatadine 0.2% at 16 and 24 hours
Time point post-CAC Visit 3 Visit 4
Duration of action 16 hours following study  
treatment
Duration of action 24 hours following study 
treatment
3 min 5 min 7 min 3 min 5 min 7 min
Active versus placebo
 Alcaftadine-placebo -1.53 -1.43 -1.13 -1.63 -1.35 -1.02
 P value ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001
 Olopatadine-placebo -1.14 -1.22 -1.08 -1.30 -1.03 -0.94
 P value ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001
Active versus active
 Alcaftadine-olopatadine -0.39 -0.20 -0.05 -0.33 -0.32 -0.08
 P value 0.026 0.273 0.798 0.073 0.117 0.710
Abbreviations: CAC, conjunctival allergen challenge; min, minutes; P, probability level.
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Figure 2 Reduction from baseline itch scores. A comparison of itch scores at visit 
3 (16 hours; A) and at visit 4 (24 hours; B) with those from visit 2 (pretreatment 
baseline visit).
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Figure 3 Comparison of minimal itch (scores , 1) data for placebo, alcaftadine 0.25%, and olopatadine 0.2% at 16 hours (A) and at 24 hours (B) after instillation of 
treatment.
time points, both at 16 hours (Figure 1A) and 24 hours 
post instillation (Figure 1B), with a statistically signifi-
cant difference at the 3-minute time point at 16 hours 
(P = 0.026; Table 2).
To assess the ability of the actives to reduce ocular itch-
ing within a population, comparisons between baseline itch 
scores for each treatment group (visit 2) and scores obtained 
in visits 3 and 4 were made; in this comparison, the observed 
treatment effects are responses in the same subjects at dif-
ferent visits rather than a parallel placebo population. The 
percent itch reduction from baseline at both 16 and 24 hours 
after treatment instillation revealed significant reductions 
from baseline (Figure 2).
The percentage of subjects reporting minimal itch (a 
score of , 1.0), is plotted for all treatments at both the 16 
and 24 hour assessments (Figure 3). The difference between 
actives was greatest at 3 minutes (16 hours after instillation), 
when 78% of subjects treated with alcaftadine 0.25% reported 
itch scores , 1 as compared with 46% of those treated with 
olopatadine 0.2% (P = 0.006). At the same time point at 
24 hours post instillation, 71% of subjects treated with alcaf-
tadine 0.25% reported minimal itch, compared with 47% of 
subjects treated with olopatadine 0.2% (P = 0.061).
The percentage of subjects reporting complete relief (itch 
score = 0) was also examined at both 16 and 24 hours after 
treatment instillation (Figure 4). Both actives exhibited a 
zero itch score in 20%–30% of subjects. A greater number 
of subjects in the alcaftadine 0.25% arm displayed zero 
itch at 3 minutes (P $ 0.192), while more subjects in the 
olopatadine 0.2% arm had zero itch at the 7-minute time 
point (P $ 0.756), although differences in zero itch were 
not statistically significant.
An alternative approach to the assessment of itch relief 
is to examine a distribution of the raw subject-reported itch 
scores (Figure 5). For each visit, subjects reported a total 
of six scores for two eyes at three time points. For subject-
reported itch score distributions, a leftward shift in score 
frequencies from baseline to drug treatment is an indicator 
of efficacy, both in terms of the degree of relief and the 
proportion of subjects whose symptoms are alleviated. In 
this study, the leftward shift seen in the alcaftadine group is 
greater than that seen in the olopatadine group, at both 16 
and 24 hours after instillation.
Secondary efficacy measures for redness, chemosis, 
lid swelling, and tearing are summarized in Table 3. 
For conjunctival redness measures, both actives 
demonstrated statistical significance relative to placebo 
in each of the three vascular beds at some but not all time 
points evaluated, and there were no significant differences 
between actives (Table 3). Both treatments provided sta-
tistically significant reductions in lid swelling and ocular 
tearing compared with placebo, and these effects were 
significant at both 16 and 24 hours after treatment instil-
lation (Table 3). For chemosis, both alcaftadine 0.25% and 
olopatadine 0.2% provided relief 16 hours after instilla-
tion, but only alcaftadine 0.25% demonstrated statistical 
significance against placebo for chemosis at every time 
point measured at 24 hours.
There were no serious adverse events in the course of 
this 5-week study. There was a total of 14 adverse events 
experienced by nine subjects, and five of these events were 
reported by one subject. Three of these occurred as a result of 
a fall, and were not treatment-related. None of the reported 
adverse events were related to any study treatments.
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Figure 5 Percent of total subject-reported itching scores in each treatment group (A–C).
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Discussion
In this comparative study, two topical formulations of 
ocular antihistamines were evaluated for their ability to 
provide a long duration of relief from itching due to allergic 
 conjunctivitis. Both olopatadine 0.2% and alcaftadine 0.25% 
are approved by the US Food and Drug Administration for 
once-daily dosing.8,9 In previous studies,10,11 duration of action 
had been measured 16 hours following instillation, and both 
treatments demonstrated substantial relief at that time point. 
The study described in this report was designed to extend that 
analysis to 24 hours post-instillation, while also providing 
a basis for direct comparison of the two antiallergic agents. 
Our comparison of alcaftadine 0.25%, olopatadine 0.2%, 
and placebo utilized the CAC model to measure duration of 
treatment efficacy in reducing ocular itching, ocular redness, 
chemosis, tearing, and lid swelling. Use of CAC is the cur-
rent standard for regulatory approval of ocular antiallergic 
agents in the US.10,11,13–18
Both treatments provided reduction in symptoms and 
signs of allergic conjunctivitis in this study. The reduction in 
ocular itching at 16 and 24 hours after treatment instillation 
was statistically significant for both olopatadine 0.2% and 
alcaftadine 0.25% compared with placebo (P , 0.0001). Eyes 
treated with alcaftadine 0.25% had significantly lower scores 
for mean ocular itching than eyes treated with olopatadine 
0.2% at 3 minutes for the 16-hour visit (P = 0.026), the earli-
est time point evaluated in the CAC model. In addition, eyes 
treated with alcaftadine 0.25% had numerically lower scores 
for mean itching than eyes treated with olopatadine 0.2% at 
all other time points for both the 16-hour and 24-hour visits. 
Both treatments also demonstrated reductions in all second-
ary endpoints.  Alcaftadine 0.25% was statistically superior 
to olopatadine 0.2% for reducing chemosis 24 hours after 
instillation.
The differences in ocular itching scores between the 
actives and placebo, as well as the differences between the two 
actives, were similar both at the 16-hour and 24-hour post-
instillation visits. The most significant difference between the 
two treatments was evidenced in the comparison of minimal 
itch (score , 1). At the 3-minute time point (16 hours after 
instillation), about 78% of subjects receiving alcaftadine 
reported minimal or no itch; in contrast, less than 50% of 
Table 3 Secondary endpoint data for both visits expressed as difference scores
Time point post-CAC Visit 3 Visit 4
Duration of action 16 hours post study  
treatment
Duration of action 24 hours post study 
treatment
7 min 15 min 20 min 7 min 15 min 20 min
Conjunctival redness
 Alcaftadine 0.25%-placebo -0.21 -0.26 -0.24 -0.34a -0.22 -0.21
 Olopatadine 0.2%-placebo -0.33a -0.30a -0.25 -0.30a -0.21 -0.28
 Alcaftadine 0.25%-olopatadine 0.2% 0.11 0.04 0.01 -0.04 -0.01 0.07
Ciliary redness
 Alcaftadine 0.25%-placebo -0.43a -0.30a -0.28 -0.48a -0.36a -0.26
 Olopatadine 0.2%-placebo -0.45a -0.32a -0.29 -0.36a -0.33 -0.28
 Alcaftadine 0.25%-olopatadine 0.2% 0.02 0.02 0.01 -0.12 -0.03 0.02
Episcleral redness
 Alcaftadine 0.25%-placebo -0.22 -0.31 -0.16 -0.36a -0.19 -0.22
 Olopatadine 0.2%-placebo -0.38a -0.36a -0.29 -0.45a -0.33 -0.35
 Alcaftadine 0.25%-olopatadine 0.2% 0.16 0.06 0.13 0.09 0.13 0.13
Chemosis
 Alcaftadine 0.25%-placebo -0.35a -0.49a -0.41a -0.25a -0.31a -0.28a
 Olopatadine 0.2%-placebo -0.27a -0.42a -0.38a -0.18 -0.25 -0.29
 Alcaftadine 0.25%-olopatadine 0.2% -0.08 -0.06 -0.02 -0.07 -0.05 0.01
Lid swelling
 Alcaftadine 0.25%-placebo -0.7a -0.8a -0.7a -0.6a -0.5a -0.5a
 Olopatadine 0.2%-placebo -0.5a -0.6a -0.6a -0.6a -0.4a -0.5a
 Alcaftadine 0.25%-olopatadine 0.2% -0.1 -0.2 -0.1 0.0 -0.1 0.0
Tearing
 Alcaftadine 0.25%-placebo -0.6a -0.5a -0.6a -0.7a -0.4a -0.3
 Olopatadine 0.2%-placebo -0.4a -0.3 -0.4 -0.6a -0.3 -0.3
 Alcaftadine 0.25%-olopatadine 0.2% -0.1 -0.2 -0.2 -0.1 -0.1 0.0
Notes: Data are from the intent-to-treat population. aP , 0.005 versus placebo using a two-sided t-test.
Abbreviations: CAC, conjunctival allergen challenge; min, minutes.
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subjects receiving olopatadine demonstrated a similar level 
of itch relief. The difference in efficacy is perhaps most 
apparent in the distribution of itch scores (Figure 5). These 
plots revealed an important difference between alcaftadine 
and olopatadine, where a greater proportion of scores for 
alcaftadine are #1.5, while the scores for olopatadine are 
evenly distributed in a range between 0 and 2.
Two previous studies have examined the therapeutic 
effects of both alcaftadine and olopatadine. An early CAC-
based clinical study found alcaftadine 0.25% was superior 
to olopatadine 0.1% for both onset and duration of anti-itch 
effects.19 The faster onset of effect is consistent with the 
findings of the present study in which statistically significant 
lower itch scores were seen at the 3-minute time point post 
allergen challenge (16 hours post instillation). In another 
preclinical study, alcaftadine was shown to have a greater 
effect than olopatadine on both eosinophil recruitment and 
epithelial junctional protein stability,20 suggesting a potential 
for greater efficacy in late-phase allergy. This result, together 
with an examination of inflammation-induced disruptions in 
ocular epithelial stability,21 suggest that efficacy differences 
between alcaftadine and olopatadine may be related to the 
greater ability of alcaftadine to prevent the disruption to the 
ocular surface that follows allergen exposure. Both rapid 
relief in ocular itching as well as long duration of action are 
keys to successful control of allergic conjunctivitis. Results 
of the current study, in combination with previous reports, 
establish that alcaftadine 0.25% can effectively address both 
of these key aspects of disease control.
Overall, this study demonstrated that both alcaftadine 
0.25% and olopatadine 0.2% were effective at preventing 
ocular itching in a CAC model beyond 16 hours. The dif-
ferences between actives and placebo and the differences 
between the two actives at 24 hours post instillation were 
similar to the findings 16 hours post instillation.  Alcaftadine 
0.25% was shown to achieve statistically signif icant 
lower mean ocular itch scores than olopatadine 0.2% at 
the earliest time point following allergen challenge. Both 
alcaftadine 0.25% and olopatadine 0.2% were safe and 
well  tolerated. Further studies are warranted to delineate 
further the actions of these two treatments and understand 
better the  mechanisms of actions potentially underlying any 
 differences in efficacy.
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